IARC致癌物

IARC对致癌物的最新评价结果 Overall Evaluations of Carcinogenicity to Humans   Group 1: Carcinogenic to humans (100)   Agents and groups of agents 4-Aminobiphenyl [92-67-1] (Vol. 1, Suppl. 7; 1987)氨基联苯 Arsenic [7440-38-2] and arsenic compounds (Vol. 23, Suppl. 7; 1987) (NB: This evaluation applies to the group of compounds as a whole and not necessarily to all individual compounds within the group) Asbestos [1332-21-4] (Vol. 14, Suppl. 7; 1987) Azathioprine [446-86-6] (Vol. 26, Suppl. 7; 1987)硫唑嘌呤 Benzene [71-43-2] (Vol. 29, Suppl. 7; 1987) Benzidine [92-87-5] (Vol. 29, Suppl. 7; 1987)对二氨二苯 Benzo[a]pyrene [50-32-8] (Vol. 32, Suppl. 7, Vol. 92; in preparation) (NB: Overall evaluation upgraded from 2B to 1 based on mechanistic and other relevant data) Beryllium [7440-41-7] and beryllium compounds (Vol. 58; 1993) N,N-Bis(2-chloroethyl)-2-naphthylamine (Chlornaphazine) [494-03-1] (Vol. 4, Suppl. 7; 1987)萘胺 Bis(chloromethyl)ether [542-88-1] and chloromethyl methyl ether [107-30-2] (technical-grade) (Vol. 4, Suppl. 7; 1987)氯甲甲醚 1,4-Butanediol dimethanesulfonate (Busulphan; Myleran) [55-98-1] (Vol. 4, Suppl. 7; 1987) 丁二醇二甲烷磺酸盐 Cadmium [7440-43-9] and cadmium compounds (Vol. 58; 1993) Chlorambucil [305-03-3] (Vol. 26, Suppl. 7; 1987) 苯丁酸氮芥 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU; Semustine) [13909-09-6] (Suppl. 7; 1987) 亚硝基脲 Chromium[VI] (Vol. 49; 1990) Ciclosporin [79217-60-0] (Vol. 50; 1990)环孢霉素 Cyclophosphamide [50-18-0] [6055-19-2] (Vol. 26, Suppl. 7; 1987) 环磷酰胺 Diethylstilboestrol [56-53-1] (Vol. 21, Suppl. 7; 1987) 己烯雌酚 Epstein-Barr virus (Vol. 70; 1997) Erionite [66733-21-9] (Vol. 42, Suppl. 7; 1987) 毛沸石 Estrogen-progestogen menopausal therapy (combined) (Vol. 72, Vol. 91; in preparation) 雌激素孕激素绝经疗法 Estrogen-progestogen oral contraceptives (combined) (Vol. 72, Vol. 91; in preparation) (NB: There is also convincing evidence in humans that these agents confer a protective effect against cancer in the endometrium and ovary) Estrogens, nonsteroidal (Suppl. 7; 1987) (NB: This evaluation applies to the group of compounds as a whole and not necessarily to all individual compounds within the group) Estrogens, steroidal (Suppl. 7; 1987) (NB: This evaluation applies to the group of compounds as a whole and not necessarily to all individual compounds within the group) Estrogen therapy, postmenopausal (Vol. 72; 1999) Ethylene oxide [75-21-8] (Vol. 60; 1994) (NB: Overall evaluation upgraded from 2A to 1 with supporting evidence from other relevant data) 乙撑氧 Etoposide [33419-42-0] in combination with cisplatin and bleomycin (Vol. 76; 2000) Formaldehyde [50-00-0] (Vol. 88; 2006) Gallium arsenide [1303-00-0] (Vol. 86; 2006) 砷化镓 [Gamma Radiation: see X- and Gamma (g)-Radiation] Helicobacter pylori (infection with) (Vol. 61; 1994) 幽门螺杆菌 Hepatitis B virus (chronic infection with) (Vol. 59; 1994) Hepatitis C virus (chronic infection with) (Vol. 59; 1994) Human immunodeficiency virus type 1 (infection with) (Vol. 67; 1996) Human papillomavirus types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 66 (Vol. 64, Vol. 90; in preparation) (NB: The HPV types that have been classified as carcinogenic to humans can differ by an order of magnitude in risk for cervical cancer) 人乳头瘤病毒 Human T-cell lymphotropic virus type I (Vol. 67; 1996) Melphalan [148-82-3] (Vol. 9, Suppl. 7; 1987) 左旋苯丙氨酸氮芥 8-Methoxypsoralen (Methoxsalen) [298-81-7] plus ultraviolet A radiation (Vol. 24, Suppl. 7; 1987) MOPP and other combined chemotherapy including alkylating agents (Suppl. 7; 1987) 氮芥 Mustard gas (Sulfur mustard) [505-60-2] (Vol. 9, Suppl. 7; 1987) 2-Naphthylamine [91-59-8] (Vol. 4, Suppl. 7; 1987)萘胺 Neutrons (Vol. 75; 2000) (NB: Overall evaluation upgraded from 2B to 1 with supporting evidence from other relevant data) Nickel compounds (Vol. 49; 1990) N'-Nitrosonornicotine (NNN) [16543-55-8] and 4-(N-Nitrosomethylamino)-1-(3-pyridyl)- 1-butanone (NNK) [64091-91-4] (Vol. 37, Suppl. 7, Vol. 89; in preparation) (NB: Overall evaluation upgraded from 2B to 1 based on mechanistic and other relevant data) [Oestrogen: see Estrogen] Opisthorchis viverrini (infection with) (Vol. 61; 1994) 香猫肝吸虫 [Oral contraceptives, combined estrogen-progestogen: see Estrogen-progestogen oral contraceptives (combined)] Oral contraceptives, sequential (Suppl. 7; 1987) Phosphorus-32, as phosphate (Vol. 78; 2001) Plutonium-239 and its decay products (may contain plutonium-240 and other isotopes), as aerosols (Vol. 78; 2001) Radioiodines, short-lived isotopes, including iodine-131, from atomic reactor accidents and nuclear weapons detonation (exposure during childhood) (Vol. 78; 2001) Radionuclides, a-particle-emitting, internally deposited (Vol. 78; 2001) (NB: Specific radionuclides for which there is sufficient evidence for carcinogenicity to humans are also listed individually as Group 1 agents) Radionuclides, b-particle-emitting, internally deposited (Vol. 78; 2001) (NB: Specific radionuclides for which there is sufficient evidence for carcinogenicity to humans are also listed individually as Group 1 agents) Radium-224 and its decay products (Vol. 78; 2001) Radium-226 and its decay products (Vol. 78; 2001) Radium-228 and its decay products (Vol. 78; 2001) Radon-222 [10043-92-2] and its decay products (Vol. 43, Vol. 78; 2001) Schistosoma haematobium (infection with) (Vol. 61; 1994) 谷胧甘肤转移酶 (Sh28GST)的重组体 Silica [14808-60-7], crystalline (inhaled in the form of quartz or cristobalite from occupational sources) (Vol. 68; 1997) Solar radiation (Vol. 55; 1992) Talc containing asbestiform fibres (Vol. 42, Suppl. 7; 1987) Tamoxifen [10540-29-1] (Vol. 66; 1996) (NB: There is also conclusive evidence that tamoxifen reduces the risk of contralateral breast cancer) 枸橼酸他莫昔芬 2,3,7,8-Tetrachlorodibenzo-para-dioxin [1746-01-6] (Vol. 69; 1997) (NB: Overall evaluation upgraded from 2A to 1 with supporting evidence from other relevant data) Thiotepa [52-24-4] (Vol. 50; 1990) 塞替派 Thorium-232 and its decay products, administered intravenously as a colloidal dispersion of thorium-232 dioxide (Vol. 78; 2001) Treosulfan [299-75-2] (Vol. 26, Suppl. 7; 1987) 曲丁磺酯 Vinyl chloride [75-01-4] (Vol. 19, Suppl. 7; 1987) X- and Gamma (g)-Radiation (Vol. 75; 2000)   Mixtures Aflatoxins (naturally occurring mixtures of) [1402-68-2] (Vol. 56, Vol. 82; 2002) 黄曲毒素类 Alcoholic beverages (Vol. 44; 1988) Areca nut (Vol. 85; 2004) (NB: Overall evaluation based on human data, animal data, and mechanistic and other relevant data) 槟榔果 Betel quid with tobacco (Vol. 85; 2004) 槟榔碱 Betel quid without tobacco (Vol. 85; 2004) Coal-tar pitches [65996-93-2] (Vol. 35, Suppl. 7; 1987) Coal-tars [8007-45-2] (Vol. 35, Suppl. 7; 1987) Herbal remedies containing plant species of the genus Aristolochia (Vol. 82; 2002) 马兜铃属 Household combustion of coal, indoor emissions from (Vol. 95; in preparation) Mineral oils, untreated and mildly treated (Vol. 33, Suppl. 7; 1987) Phenacetin, analgesic mixtures containing (Suppl. 7; 1987) 乙酰对氨苯乙醚，非那西汀 Salted fish (Chinese-style) (Vol. 56; 1993) Shale-oils [68308-34-9] (Vol. 35, Suppl. 7; 1987) Soots (Vol. 35, Suppl. 7; 1987) Tobacco, smokeless (Vol. 37, Suppl. 7, Vol. 89; in preparation) Wood dust (Vol. 62; 1995)   Exposure circumstances Aluminium production (Vol. 34, Suppl. 7; 1987) Arsenic in drinking-water (Vol. 84; 2004) Auramine, manufacture of (Suppl. 7; 1987) 代甲亚胺盐酸盐; Boot and shoe manufacture and repair (Vol. 25, Suppl. 7; 1987) Chimney sweeping (Vol. 92; in preparation) Coal gasification (Vol. 34, Suppl. 7, Vol. 92; in preparation) Coal-tar distillation (Vol. 92; in preparation) Coke production (Vol. 34, Suppl. 7, Vol. 92; in preparation) Furniture and cabinet making (Vol. 25, Suppl. 7; 1987) Haematite mining (underground) with exposure to radon (Vol. 1, Suppl. 7; 1987) 赤铁矿 Involuntary smoking (exposure to secondhand or 'environmental' tobacco smoke) (Vol. 83; 2004) Iron and steel founding (Vol. 34, Suppl. 7; 1987) Isopropyl alcohol manufacture (strong-acid process) (Suppl. 7; 1987) 异丙醇 Magenta, manufacture of (Vol. 57; 1993) 红色苯胺染料 Painter (occupational exposure as a) (Vol. 47; 1989) Paving and roofing with coal-tar pitch (Vol. 92; in preparation) Rubber industry (Vol. 28, Suppl. 7; 1987) Strong-inorganic-acid mists containing sulfuric acid (occupational exposure to) (Vol. 54; 1992) Tobacco smoking and tobacco smoke (Vol. 83; 2004) Last updated: 13 December 2006     Group 2A: Probably carcinogenic to humans(68)   Agents and groups of agents   Acrylamide [79-06-1] (Vol. 60; 1994) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Adriamycin [23214-92-8] (Vol. 10, Suppl. 7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Androgenic (anabolic) steroids (Suppl. 7; 1987) Aristolochic acids (naturally occurring mixtures of) (Vol. 82; 2002) Azacitidine [320-67-2] (Vol. 50; 1990) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Benzidine-based dyes (Suppl. 7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Bischloroethyl nitrosourea (BCNU) [154-93-8] (Vol. 26, Suppl.7; 1987) 1,3-Butadiene [106-99-0] (Vol. 71; 1999) Captafol [2425-06-1] (Vol. 53; 1991) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Chloramphenicol [56-75-7] (Vol. 50; 1990) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) -Chlorinated toluenes (benzal chloride [98-87-3], benzotrichloride [98-07-7], benzyl chloride [100-44-7]) and benzoyl chloride [98-88-4] (combined exposures) (Vol. 29, Suppl. 7, Vol. 71; 1999) 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) [13010-47-4](Vol. 26, Suppl. 7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) 4-Chloro-ortho-toluidine [95-69-2] (Vol. 77; 2000) Chlorozotocin [54749-90-5] (Vol. 50; 1990) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Cisplatin [15663-27-1] (Vol. 26, Suppl. 7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Clonorchis sinensis (infection with) (Vol. 61; 1994) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Cyclopenta[cd]pyrene [27208-37-3] (Vol. 32, Suppl. 7, Vol. 92; in preparation) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Dibenz[a,h]anthracene [53-70-3] (Vol. 32, Suppl. 7, Vol. 92; in preparation) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Dibenzo[a,l]pyrene [191-30-0] (Vol. 32, Suppl. 7, Vol. 92; in preparation) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Diethyl sulfate [64-67-5] (Vol. 54, Vol. 71; 1999) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Dimethylcarbamoyl chloride [79-44-7] (Vol. 12, Suppl. 7, Vol. 71; 1999) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) 1,2-Dimethylhydrazine [540-73-8] (Vol. 4, Suppl. 7, Vol. 71; 1999) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Dimethyl sulfate [77-78-1] (Vol. 4, Suppl. 7, Vol. 71; 1999) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Epichlorohydrin [106-89-8] (Vol. 11, Suppl. 7, Vol. 71; 1999) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Ethylene dibromide [106-93-4] (Vol. 15, Suppl. 7, Vol. 71; 1999) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) N-Ethyl-N-nitrosourea [759-73-9] (Vol. 17, Suppl.7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Etoposide [33419-42-0] (Vol. 76; 2000) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Glycidol [556-52-5] (Vol. 77; 2000) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Indium phosphide [22398-80-7] (Vol. 86; 2006) (NB: Overall evaluation upgraded from 2B to 2A) IQ (2-Amino-3-methylimidazo[4,5-f]quinoline) [76180-96-6] (Vol. 56; 1993) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Kaposi's sarcoma herpesvirus/human herpesvirus 8 (Vol. 70; 1997) Lead compounds, inorganic (Vol. 87; 2006) 5-Methoxypsoralen [484-20-8] (Vol. 40, Suppl. 7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) 4,4´-Methylene bis(2-chloroaniline) (MOCA) [101-14-4] (Vol.57; 1993) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Methyl methanesulfonate [66-27-3] (Vol. 7, Suppl. 7, Vol. 71; 1999) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) N-Methyl-N´-nitro-N-nitrosoguanidine(MNNG) [70-25-7] (Vol. 4, Suppl. 7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) N-Methyl-N-nitrosourea [684-93-5] (Vol. 17, Suppl.7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Nitrate or nitrite (ingested) under conditions that result in endogenous nitrosation (Vol. 94; in preparation) Nitrogen mustard [51-75-2] (Vol. 9, Suppl. 7; 1987) N-Nitrosodiethylamine [55-18-5] (Vol. 17, Suppl. 7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) N-Nitrosodimethylamine [62-75-9] (Vol. 17, Suppl. 7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Phenacetin [62-44-2] (Vol. 24, Suppl. 7; 1987) Procarbazine hydrochloride [366-70-1] (Vol. 26, Suppl. 7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Styrene-7,8-oxide [96-09-3] (Vol. 60; 1994) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Teniposide [29767-20-2] (Vol. 76; 2000) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Tetrachloroethylene [127-18-4] (Vol. 63; 1995) ortho-Toluidine [95-53-4] (Vol. 77; 2000) Trichloroethylene [79-01-6] (Vol. 63; 1995) 1,2,3-Trichloropropane [96-18-4] (Vol. 63; 1995) Tris(2,3-dibromopropyl) phosphate [126-72-7] (Vol. 20, Suppl. 7, Vol. 71;1999) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Ultraviolet radiation A (Vol. 55; 1992) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Ultraviolet radiation B (Vol. 55; 1992) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Ultraviolet radiation C (Vol. 55; 1992) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Vinyl bromide [593-60-2] (Vol. 39, Suppl. 7, Vol. 71; 1999) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Vinyl fluoride [75-02-5] (Vol. 63; 1995)   Mixtures Creosotes [8001-58-9] (Vol. 35, Suppl. 7, Vol. 92; in preparation) Diesel engine exhaust (Vol. 46; 1989) High-temperature frying, emissions from (Vol. 95; in preparation) Hot mate (Vol. 51; 1991) Household combustion of biomass fuel (primarily wood), indoor emissions from (Vol. 95; in preparation) Non-arsenical insecticides (occupational exposures in spraying and application of) (Vol. 53; 1991) Polychlorinated biphenyls [1336-36-3] (Vol. 18, Suppl. 7; 1987)   Exposure circumstances Art glass, glass containers and pressed ware (manufacture of) (Vol. 58; 1993) Carbon electrode manufacture (Vol. 92; in preparation) Cobalt metal with tungsten carbide (Vol. 86; 2006) Hairdresser or barber (occupational exposure as a) (Vol. 57; 1993) Petroleum refining (occupational exposures in) (Vol. 45; 1989) Sunlamps and sunbeds (use of) (Vol. 55; 1992) Last updated: 29 November 2006     Group 2B: Possibly carcinogenic to humans (246)   Agents and groups of agents   A--C (2-Amino-9H-pyrido[2,3-b]indole) [26148-68-5] (Vol. 40, Suppl. 7; 1987) Acetaldehyde [75-07-0] (Vol. 36, Suppl. 7, Vol. 71; 1999) Acetamide [60-35-5] (Vol. 7, Suppl. 7, Vol. 71; 1999) Acrylonitrile [107-13-1] (Vol. 71; 1999) AF-2 [2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide] [3688-53-7] (Vol.31, Suppl. 7; 1987) Aflatoxin M1 [6795-23-9] (Vol. 56; 1993) para-Aminoazobenzene [60-09-3] (Vol. 8, Suppl. 7; 1987) ortho-Aminoazotoluene [97-56-3] (Vol. 8, Suppl. 7; 1987) 2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole [712-68-5] (Vol. 7, Suppl. 7; 1987) Amsacrine [51264-14-3] (Vol. 76; 2000) ortho-Anisidine [90-04-0] (Vol. 73; 1999) Antimony trioxide [1309-64-4] (Vol. 47; 1989) Aramite® [140-57-8] (Vol. 5, Suppl. 7; 1987) Auramine [492-80-8] (technical-grade) (Vol. 1, Suppl. 7; 1987) Azaserine [115-02-6] (Vol. 10, Suppl. 7; 1987) Aziridine [151-56-4] (Vol. 9, Suppl. 7, Vol. 71; 1999) (NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from other relevant data) Benz[j]aceanthrylene [202-33-5] (Vol. 92; in preparation) (NB: Overall evaluation upgraded from 3 to 2B with supporting mechanistic and other relevant data) Benz[a]anthracene [56-55-3] (Vol. 32, Suppl. 7, Vol. 92; in preparation) Benzo[b]fluoranthene [205-99-2] (Vol. 32, Suppl. 7, Vol. 92; in preparation) Benzo[j]fluoranthene [205-82-3] (Vol. 32, Suppl. 7, Vol. 92; in preparation) Benzo[k]fluoranthene [207-08-9] (Vol. 32, Suppl. 7, Vol. 92; in preparation) Benzofuran [271-89-6] (Vol. 63; 1995) Benzo[c]phenanthrene [195-19-7] (Vol. 32, Suppl. 7, Vol. 92; in preparation) (NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from other relevant data) Benzyl violet 4B [1694-09-3] (Vol. 16, Suppl. 7; 1987) 2,2-Bis(bromomethyl)propane-1,3-diol [3296-90-0] (Vol. 77; 2000) Bleomycins [11056-06-7] (Vol. 26, Suppl. 7; 1987) (NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from other relevant data) Bracken fern (Vol. 40, Suppl. 7; 1987) Bromodichloromethane [75-27-4] (Vol. 52, Vol. 71; 1999) Butylated hydroxyanisole (BHA) [25013-16-5] (Vol. 40, Suppl. 7;1987) -Butyrolactone [3068-88-0] (Vol. 11, Suppl. 7, Vol. 71; 1999) Caffeic acid [331-39-5] (Vol. 56; 1993) Carbon black [1333-86-4] (Vol. 65, Vol. 93; in preparation) Carbon tetrachloride [56-23-5] (Vol. 20, Suppl. 7, Vol. 71; 1999) Catechol [120-80-9] (Vol. 15, Suppl. 7, Vol. 71; 1999) Chlordane [57-74-9] (Vol. 79; 2001) Chlordecone (Kepone) [143-50-0] (Vol. 20, Suppl. 7; 1987) Chlorendic acid [115-28-6] (Vol. 48; 1990) para-Chloroaniline [106-47-8] (Vol. 57; 1993) 3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone [77439-76-0] (Vol. 84; 2004) Chloroform [67-66-3] (Vol. 73; 1999) 1-Chloro-2-methylpropene [513-37-1] (Vol. 63; 1995) Chlorophenoxy herbicides (Vol. 41, Suppl. 7; 1987) 4-Chloro-ortho-phenylenediamine [95-83-0] (Vol. 27, Suppl.7; 1987) Chloroprene [126-99-8] (Vol. 71; 1999) Chlorothalonil [1897-45-6] (Vol. 73; 1999) Chrysene [218-01-9] (Vol. 32, Suppl. 7, Vol. 92; in preparation) CI Acid Red 114 [6459-94-5] (Vol. 57; 1993) CI Basic Red 9 [569-61-9] (Vol. 57; 1993) CI Direct Blue 15 [2429-74-5] (Vol. 57; 1993) Citrus Red No. 2 [6358-53-8] (Vol. 8, Suppl. 7; 1987) Cobalt [7440-48-4] and cobalt compounds (Vol. 52; 1991) (NB: Evaluated as a group) Cobalt sulfate [10026-24-1] and other soluble cobalt(II) salts (Vol. 86; 2006) para-Cresidine [120-71